Development of DNA topoisomerase II-mediated anticancer agents, 3-(9-acridinylamino)-5-hydroxymethylanilines (AHMAs) and related compounds

Curr Med Chem. 2002 Sep;9(18):1677-88. doi: 10.2174/0929867023369231.

Abstract

A series of potential topoisomerase II-mediated anticancer 9-anilinoacridine derivatives, which are designed to avoid bio-oxidation and possessed long duration of drug action, is reviewed. Among these agents, 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA) derivatives and their alkylcarbamates have been investigated and developed for potential clinical application.

Publication types

  • Review

MeSH terms

  • Acridines / chemistry*
  • Acridines / metabolism
  • Acridines / pharmacology*
  • Aniline Compounds / chemistry*
  • Aniline Compounds / metabolism
  • Aniline Compounds / pharmacology*
  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • DNA / metabolism
  • Drug Design
  • Humans
  • Oxidation-Reduction
  • Structure-Activity Relationship
  • Topoisomerase II Inhibitors*

Substances

  • 3-(9-acridinylamino)-5-hydroxymethylaniline
  • Acridines
  • Aniline Compounds
  • Antineoplastic Agents
  • Topoisomerase II Inhibitors
  • DNA